http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Summit to Present New Data on C difficile Antib...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT TO PRESENT NEW DATA ON C. DIFFICILE ANTIBIOTIC PROGRAMME AT ICAAC 2013

Oxford, UK, 4 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection ('CDI'), announces that clinical and preclinical data on its novel, selective antibiotic SMT19969 for the treatment of CDI will be reported in podium and poster presentations at the 53rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy ('ICAAC') meeting in Denver, Colorado, USA from 10-13 September 2013.

Summit has been selected by an expert panel of the American Society for Microbiology to give an oral presentation summarising SMT19969 in the 'Early New Antimicrobial Agents Poster Summary Session', which will highlight the next wave of compounds with potential to move through the clinical development process. This presentation will feature Phase 1 clinical trial and preclinical data which will be included in five posters being reported by Summit and its key collaborators during the conference.

Glyn Edwards, Chief Executive Officer of Summit commented: "Summit is pleased to have been selected to showcase the data on our novel and selective antibiotic SMT19969 for the treatment of C. difficile infection at this major international conference."

Further details about the presentations are below and the full abstracts are available online at www.icaac.org/index.php/online-program-planner.

Tuesday 10 September 2013

Oral Presentation: Early New Antimicrobial Agents Poster Summary Session (2.30-4.30pm MDT)

SMT19969: A Selective Therapy for C. difficile Infection (R Vickers)

Poster Session 018: Clostridium difficile (12.00-2.00pm MDT)

K-167 Effects of a Novel Antimicrobial (SMT19969) for Treatment of Clostridium difficile Infection (CDI) on Gut Flora; EL Best, R Vickers, M Wilcox.

Wednesday 11 September 2013

Poster Session 082: Agents Acting Against Clostridium difficile (11:00am-1:00pm MDT)

F-624 Comparative in vitro Activity of SMT19969, a New Antimicrobial Agent, Against Clostridium difficile and 203 Gram-positive Aerobic and Anaerobic Gut Flora Isolates; EJ Goldstein, DM Citron.

F-625 SMT19969: Effects of Varying MIC Parameters on the in vitro activity against Clostridium difficile; A Wise, D Corbett, P Thommes, S Birchall, R Vickers, PA Warn.

F-626 SMT19969 for Clostridium difficile Infection (CDI): Phase 1 Study Investigating Safety and Pharmacokinetics in Healthy Male Subjects; R Vickers, N Robinson, E Best, M Wilcox, G Tillotson, R Echols.

F-631b Comparative in vitro activity of SMT19969, a new antimicrobial agent against 169 less common intestinal clostridium species: Implications for recurrence; EJC Goldstein, DM Citron.

Copies of these presentations will be available on the Summit website during the ICAAC meeting.

- END -

Trying 10p again.

Yep, looking good ...but expecting profit taking this afternoon.. however, I'm staying in for a long while yet!

Topped up on LBB ... looking interesting ahead of results due soon.

Looks good, although tends to + or - 10%. Good to hold more for the future.

Still looking skywards.

N+1 Singer needs to update this share. They are slow sometimes. :-))

Buying at 12p :-))

A 2 bagger for me and still looking up.

SUMMIT PRESENTS NEW PRECLINICAL AND CLINICAL DATA ON SELECTIVE C. DIFFICILE ANTIBIOTIC SMT19969 AT ICAAC 2013

:-))

Summit presentations points to antibiotic's potential
By Ian Lyall September 11 2013, 7:33am The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.

Drug developer Summit (LON:SUMM) is presenting data that points to the huge potential of its antibiotic in tackling the C.difficile superbug.

The results from studies of SMT19969 are being presented at a prestigious industry event in Colorado.

Delegates will be told that the company’s phase-one clinical trial of 56 healthy volunteers revealed the drug to be well tolerated in all doses and sparing on gut flora.

The major bacteria groups were largely unchanged with the exception of total Clostridia, which were reduced during treatment.

Results from preclinical efficacy studies were similarly encouraging.

Evaluating the potency and selectivity of SMT19969, they reveal it is highly targeted, but kills all strains of C.diff tested.

A separate analysis of SMT19969 reveals its use with traditional antibiotics does not diminish its potency.

The data will be revealed in five posters and podium presentation at the 53rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (IAAC) meeting in Denver.

Summit chief executive Glyn Edwards said: "These new data presented at ICAAC 2013 further validates the promise of SMT19969 as a novel and highly targeted antibiotic for the treatment of this serious infectious disease.

"These results demonstrate that SMT19969 selectively kills all C.difficile strains tested, is highly sparing of healthy gut flora and shows no reduction in activity when used in combination with other antibiotics. This profile is encouraging for treating CDI and significantly reducing rates of recurrent disease and we look forward to advancing SMT19969 into phase-two clinical trials in the second half of 2014."

Come on N+1 Singer upgrades needed fast.

Come on N+1 Singer upgrades needed fast.

Just taken some more off of the table here @13.61

Closed up 17.71%

You lucky guys - I never joined unfortunately although I have looked at them for years. Well done.

:-))

Another good day.

Doing well and I did not join, should have got in weeks ago but hey ho. Well done to all that did.

Profit taking today, with the usual 10% fall after a good rise.